Exotic Newcastle Disease (END) outbreak in Southern California, a highthroughput real-time reverse transcriptase-polymerase chain reaction (RRT-PCR) system was developed to respond to the large diagnostic and surveillance sample workload. A 96-well RNA extraction method, using magnetic bead technology, combined with a 96-well RRT-PCR assay, allowed 1 technician to process and test more than 400 samples per day. A 3-technician team could complete testing on approximately 1,900 samples per day. The diagnostic sensitivity of the high-throughput RRT-PCR assay was 0.9967 (95% CI 0.9937-0.9997) based on 926 virus isolation confirmed positive samples. Diagnostic specificity using an initial 434 virus isolation confirmed negative samples was 100%. A diagnostic specificity of 0.9999 (95% CI 0.9999, Ͼ0.9999) was subsequently calculated on the basis of 2 false-positive results among 65,343 surveillance samples collected after the final END-positive case was confirmed in May 2003. Assay performance over 500 replicates, including reproducibility of the combined extraction and RRT-PCR amplification steps yielded a standard deviation of 0.70 RRT-PCR cycle thresholds (Ct) and a standard deviation of 0.59 Ct for the RRT-PCR steps alone. The high-throughput RRT-PCR developed for END contributed significantly to the 2002-2003 END control effort, reducing the predicted timeline for eradication from 3 years to just 11 months, primarily because of the large number of samples that could be rapidly tested. The 96-well approach described for high-throughput END RRT-PCR could be adapted to other rapid, high-volume testing needs, as required for potential foreign animal disease responses or intensive surveillance efforts.
Introduction
Exotic Newcastle disease (END) virus is an enveloped, nonsegmented, single-stranded, negative sense RNA virus in the avian paramyxovirus-1 (APMV-1) family, and distinguished from lentogenic APMV-1 Newcastle disease viruses and pigeon paramyxoviruses by specific patterns of basic amino acids located at the virus fusion protein cleavage site (http://www.oie.int/ eng/normes/mmanual/A00036.htm). 15 Exotic Newcastle disease virus (END) is the etiological agent of a highly contagious infection 2,3 of many avian species 10 and causes devastating epidemics in poultry. Because of its economic importance, END is categorized as an OIE List A disease and a foreign animal disease throughout the United States.
Exotic Newcastle disease was detected in late September 2002 in Southern California game chickens 11 and subsequently found to be widespread in that pop-ulation. By December 2002, the disease had spread to regional commercial poultry, 12 and in January 2003 was identified in 2 adjoining states.
Development and use of technologies to rapidly identify infected birds was considered a critical step in controlling the spread of END during the 2002-2003 California outbreak. Virus isolation, the gold standard for the detection of END, was used to diagnose the first END case in late September 2002, but was not practical for routine detection during END control efforts. The primary weaknesses of virus isolation included routine turn-around times that could exceed 5-10 days and inability to rapidly distinguish between lentogenic strains, vaccine virus, and the more virulent END virus. In addition, the amplification of live END increased the potential risk of laboratory contamination, a specific biosafety concern when working with a foreign animal disease. A new approach for rapid END detection and diagnosis was needed. Real-time reverse transcriptase-polymerase chain reaction (RRT-PCR) was considered an excellent choice because the technique is rapid, eliminates the requirement for post-PCR detection steps, minimizes the risk of laboratory contamination, and offers nonsubjective reporting of results. 7, 13 Real-time PCR relies on specific, fluores-cence-labeled probes, which in the case of END virus and other APMV-1 strains could be designed to differentially target the pathogenicity marker at the fusion protein cleavage site of APMV-1 viruses. In the months after USDA National Veterinary Services Laboratory confirmation of END in California, a singletube RRT-PCR approach was cooperatively developed and validated by the USDA. 19 The design was based on flock testing, assuming overall diagnostic sensitivity would be enhanced through the sampling of multiple birds from a single flock. The approach consisted of 2 single-tube RRT-PCR assays, an initial screening assay using a matrix-protein target to detect all APMV-1, followed by a second confirmatory RRT-PCR assay targeting the fusion protein cleavage site sequences specific to END virus. 19 The maximum number of END outbreak samples tested daily using the single-tube approach as proposed by USDA was constrained by individual sample handling, centrifugation or vacuum processing steps, and thermocycler capacity. Despite improved diagnostic turn-around resulting from use of the single-tube RRT-PCR early in the outbreak compared with virus isolation, diagnostic laboratories continued to be faced with the challenge of handling an increasing number of samples for END virus detection from both flocks and individual birds. To enhance technical efficiency and laboratory capacity to respond to high sample workload from initially dozens of samples per month in December 2002 to greater than 1,500 surveillance samples per day by July 2003, efforts were focused on sample processing modifications that would greatly expand the number of diagnostic samples assayed daily by RRT-PCR. Robotics, as used for PCR-based testing of West Nile virus or foot-and-mouth disease, were considered but had capacity limited to approximately 400 samples per day. 14, 16 The purpose of this article is to document a 96-well extraction and PCR approach for successfully increasing, by 10-fold, the number of samples tested by RRT-PCR to respond to the 2002-2003 END disease outbreak. The high-throughput approach used could be adapted readily to other disease and surveillance efforts requiring PCR testing of large numbers of samples.
Materials and methods
Samples. From December 2002 through December 2003, a total of 81,943 samples from END field investigations and associated surveillance were collected in California. The samples included 80,477 swab samples and 1,466 allantoic fluids after virus isolation attempts using tissue pools (n ϭ 1,266) and swab samples (n ϭ 200). The last confirmed END-positive sample from the outbreak was collected on May 26, 2003. Between June 1, 2003, and December 31, 2003 , 65,345 avian swab samples were collected for ongoing END surveillance purposes. Outbreak and surveillance samples originated both within and beyond the USDA quarantine zones for END from commercial poultry, game chickens, game fowl, pet birds (i.e., cockatiels, parakeets, parrots), and wild birds including nonpoultry avian species such as dove, emu, duck, goose, owl, peafowl, pheasant, pigeon, and quail. All swab samples were collected by the END task force or accredited veterinarians using the designated USDA Task Force protocol identifying appropriate sample type and statistical sample size requirements. 18 Samples included oropharyngeal, tracheal, or cloacal swabs collected in 1-5 ml of brain heart infusion broth and allantoic fluid from virus isolation attempts in eggs. The swab samples included individual tracheal (n ϭ 19,519), oropharyngeal (n ϭ 13,890), and cloacal swabs (n ϭ 39,820) and pools of up to 5 swabs from a single premise or up to 5 swabs per house for commercial premise and species (n ϭ 6,042) as well as environmental swabs (n ϭ 857), other specimens (n ϭ 349) and allantoic fluids from virus isolation attempts (n ϭ 1,466). Swabs were removed from the collection fluid when received by the laboratory, and swab fluid was kept at 4 C or Ϫ20 C until tested by egg inoculation and RRT-PCR. The origin of the samples and results of previous testing were blinded to the technical staff performing the virus isolation and PCR assays.
Virus isolation. Virus isolation was performed according to standard procedures. 2 In brief, each of three 9-11-day-old embryonating specific pathogen free chicken eggs was inoculated with 0.2 ml swab fluid by the chorioallantoic sac route. The eggs were incubated at 37 C for either 3 or 5 days, and candled daily.
For eggs incubated 3 days, all amnioallantoic fluids (AAF) regardless of embryo mortality were tested for the presence of hemagglutinating antigen (HA). Hemagglutinating specimens were tested by hemagglutination inhibition using APMV-1-specific antisera, and if positive, characterized by sequence analysis of the virus fusion protein gene. The specific amino acid sequence between positions 112 and 117 at the fusion protein cleavage site were used to confirm and differentiate lentogenic APMV-1, pigeon paramyxovirus-1 (PPMV-1) and END (http://www.oie.int/eng/normes/mmanual/ A00036.htm). 5, 15 For eggs incubated 5 days, AAF were harvested and tested as above from only those eggs showing embryo mortality. Embryo lethal specimens that did not agglutinate chicken erythrocytes were reinoculated as above. If specimens were negative for embryo mortality on the second passage, results were recorded as negative for END virus. If specimens were embryo lethal and HA negative, additional testing for bacterial contaminants and alternate viruses was pursued.
Virus identification and characterization. The 96-well END RRT-PCR assay was developed and optimized using clinical samples previously confirmed positive or negative for END by virus isolation and hemagglutination inhibition using standard procedures. 4 The samples were additionally evaluated by the previously described single-tube END RRT-PCR, which amplifies a 100-base pair (bp) target inclusive of the fusion protein cleavage site. 19 For selected samples, additional primer sets, also encompassing the fusion protein cleavage site but providing larger PCR amplicons of 202 bp 5 and 254 bp 15 , were used to provide amplicons of sufficient size for direct sequence analysis of the RRT-PCR product. The amino acid sequence at the fusion protein cleavage site was used to characterize the virus as END, APMV-1, or PPMV-1 as described previously (http://www.oie.int/eng/ normes/mmanual/A00036.htm). 5, 15 High-throughput PCR assay. The high-throughput RRT-PCR approach used a 96-well microtiter format for both extraction and PCR steps. Sample handling was minimized by use of distance-adjustable automated 8-or 12-channel pipetters a to transfer samples directly from sample storage tubes to microtiter plates. Polymerase chain reaction reagent mixes were pre-prepared, transferred to 96-well plates, and stored at Ϫ20 C protected from light for up to 1 wk.
Single-tube RNA extraction. A phenol-chloroform-based extraction using phase lock gel tubes b and Trizol LS reagent c was designated the ''gold standard'' for RNA extraction. Phase lock gel tubes were centrifuged for 30 sec at 12,000 ϫ g, and 750 l Trizol LS c plus 250 l of vortex-mixed sample were added to the phase lock tube and mixed by inverting the tube; 200 l chloroform was added, followed by an additional vortex step for 2 min. Tubes were incubated for 5 min at room temperature, followed by centrifugation at 12,200 ϫ g for 15 min at 4 C. The supernatant was decanted into clean microcentrifuge tubes. To each sample, 15 l of yeast t RNA c (1 g/l) and 500 l of 100% isopropyl alcohol were added. The samples were mixed well, incubated 10 min at room temperature, followed by centrifugation at 12,200 ϫ g for 10 min at 4 C. After discarding the supernatant, the pellet was washed with 1 ml ice-cold 75% ethanol. Subsequently, a pulse vortex and a centrifugation step at 7,500 ϫ g for 5 min at 4 C were performed. After discarding the liquid, the inside of the tube was blotted dry using an autoclaved Kimwipe tissue d without disturbing the pellet. The RNA pellet was vacuum dried e for 10 min and RNA resuspended in 18 l sterile water using 3 cycles of pulse vortexing. Ribonucleic acid was stored at Ϫ70 C until use.
The 96-well RNA extraction. A commercial RNA extraction kit f based on technology for magnetic bead binding of total RNA was used according to the manufacturer's recommendation. Beads were pretreated as follows: 50 l bead stock solution was washed twice in 65-80 C nuclease free water, vortexed, and pelleted on a 96-well magnetic stand. f After discarding the supernatant, the beads were resuspended in 2 ml of the manufacturer's bead suspension solution. f Lysis/binding f solution, DNase I, f and wash buffer f were diluted according to the manufacturer's recommendations. Yeast t RNA c was added at a concentration of 43 g/ml to the lysis/ binding solution.
Fifty microliters of a swab sample followed by 120 l lysis/binding solution were placed into wells of a 96-well round-bottom polystyrene plate g using 8-channel expandable pipetters a to facilitate sample handling. The samples were lysed while shaking for 5 min on an orbital plate shaker, h 20 l of the washed magnetic beads was added, and mixed for 2 min. The 96-well plate was placed for 1 min on the magnetic stand to pellet the beads, and supernatant was discarded by using expandable pipetters. One hundred microliters of wash buffer was added to each well, and samples were washed by shaking on an orbital shaker for 2 min. Beads were pelleted using a magnetic stand and the supernatant was discarded. Twenty-five microliters of diluted DNase I f (4 units/well) was added, and the plate was incubated while rotating for 15 min at room temperature. After DNase I digestion, 120 l lysis/binding solution was added and mixed by rotating for 1.5 min. Beads were pelleted, supernatant was discarded, and the lysis/binding solution step was repeated. After discarding the supernatant, 150 l wash buffer was added to each well and plate was shaken for 1.5 min. Beads were pelleted, the supernatant was discarded, and the wash step was repeated. After discarding the supernatant, the plate was shaken at maximum speed for 3 min to dry the bead pellet. The RNA was eluted by adding 25 l hot (70-80 C) RNase-free water, f and the plate was shaken at maximum speed for 3 min. Eluted RNA was either stored in the 96-well plate with the magnetic beads for less than 4 hr at 4 C or transferred into wells of a clean plate, covered with plate sealing tape i and frozen at Ϫ70 C until used in the RRT-PCR assay.
Real-time reverse transcriptase-polymerase chain reaction. A RRT-PCR mastermix containing 0.15 l RNA-free water f , 2.5 l 10 ϫ PCR buffer c , 3 l MgCl c (50 mM), 1 l deoxynucleoside triphosphate (dNTP) Mix j (10 mM each), 0.15 l 100 M forward primer k,19 , 0.15 l 100 M reverse primer k,19 , 1 l Rnase Inhibitor l (adjusted to a final concentration of 10 U), 0.25 l Superscript II c (200 U/l), 0.3 l Platinum Taq c (5 U/l), and 0.5 l probe k, 1,19 (TaqMan probe labeled with FAM and a BHQ-1 quencher) was prepared. Nine microliters of this mastermix was dispensed into each well of a 96-well PCR plate m and either used immediately or stored at Ϫ20 C, sealed i and protected from light for up to 1 wk. To perform the RRT-PCR, 16 l of extracted RNA was transferred to each well of 96-well plates containing the PCR mastermix. Alternatively, a custom-made mastermix of RRT-PCR enzymes and buffers c was used. Four microliters of 5ϫ reaction mix c was mixed with 5.2 l RNA-free water, f 0.15 l 100 M forward primer, k,19 0.15 l 100 M reverse primer k,19 , 1 l enzyme mix, c 0.5 l 10 M probe k (TaqMan probe labeled with FAM and a BHQ-1 quencher). 1, 19 A 96well PCR plate m was preloaded with 11 l of this mastermix into each well and either used immediately or stored at Ϫ20 C, sealed i and protected from light for up to 1 wk. To perform the RRT-PCR, 14 l of extracted RNA was transferred to each well of 96-well plates containing the PCR mastermix.
A 96-well real-time PCR thermocycler m was programmed with an initial 30-min reverse transcriptase time at 48 C, followed by 2 min at 95 C. Thermocycling conditions were programmed for 15 sec at 94 C, 30 sec at 58 C, and 15 sec at 72 C for a total of 35 cycles. The manufacturer's software m was used with the default options, with the exception of the baseline option set at 10 times the standard deviation of the cycle range between 8 and 14 cycles to mimic the USDAvalidated single-tube RRT-PCR protocol performed using different thermocycling equipment.
Quality control. Each assay microtiter plate included 4 quality control samples. A well-characterized END virus from a clinical case (#519) was amplified in eggs, and al-lantoic fluid harvested for use as END virus extraction and PCR-positive controls. Reference La Sota APMV-1 Newcastle disease vaccine strain was used as the END-negative PCR but positive extraction control (the fusion protein target is amplified by the primer set, but the probe site is a mismatch for END virus). Of the 4 controls on each 96-well plate, 2 were PCR controls and 2 were extraction controls used to evaluate extraction efficiency and to monitor for the possibility of well-to-well cross-contamination. The La Sota vaccine strain extraction control was placed into well C3 of the 96-well microtiter plate and the strong positive END control (#519) was placed into well F8. La Sota strain RNA and #519 RNA PCR controls, both previously extracted with the designated gold standard Trizol LS protocol, were added after completion of the bead extraction step into wells at the lower right corner of the plate at positions H11 and H12.
Initially, quality control limits for the extraction and PCR control samples, which were included on every 96-well plate, were based on Ϯ5 RRT-PCR cycle thresholds (Ct) from the control's expected Ct value, using the single-tube END RRT-PCR criteria. The quality control limits for a valid assay were later modified to a limit of Ϯ1.5 Ct after evaluating performance of replicates on 50 individual 96-well plates. To further enhance quality control, the maximum difference on a single plate between the Ct value of the extraction control and the Ct value of PCR control was limited to 3.0 Ct, equivalent to approximately 1 log of virus. All 96well plate assays not meeting the quality control limits were repeated, investigated, and documented in terms of technical problems, new personnel in training, or as unidentified source of failure. Potential for cross-contamination, defined as END virus or RNA contamination of the original swab sample, extracted RNA, or PCR amplicon during sample handling or testing that could result in a false-positive RRT-PCR result, was also investigated.
Gel electrophoresis. The PCR products from 100% of the tested samples were transferred to agarose gels for confirmation of the PCR amplicon size. After RRT-PCR, the 96well plates containing PCR products were immediately frozen at Ϫ20 C. To prevent sample cross-contamination because of condensation flowing into the wells, the plate was thawed with the lid removed in a hepa-filtered laminar-flow hood. Twenty-five microliters of post-PCR sample was mixed with gel loading buffer n in a 5:1 ratio. Precast 4% agarose gels o were loaded with 6 l loading buffer/sample mix or DNA ladder c mix (3 l DNA ladder and 3 l loading buffer) and electrophoresed in TBE buffer, pH 8.6 at 210 V for 22 min on a 96-well gel system p . Gel documentation was performed using a fluorescent imager. q
Real-time reverse transcriptase-polymerase chain reaction interpretation. Swab samples were identified as END RRT-PCR positive when a Ct between 14 and 35 cycles was reported, and a 100-bp amplicon was detected by gel electrophoresis. A sample was termed as false positive by END RRT-PCR when a PCR Ct between 14 and 35 Ct was reported, but no 100-bp amplicon was detected by gel electrophoresis. All false-positive results were confirmed by repeat virus isolation attempts from the original clinical or surveillance swab sample.
A sample was termed negative by END RRT-PCR when no threshold crossing was detected before 36 cycles and a 100-bp amplicon was not detected. An END RRT-PCR result was termed false negative when no Ct was reported before 36 cycles but a 100-bp amplicon was detected by gel electrophoresis, and confirmed as END virus positive using an alternative END primer set 5, 15 followed by direct sequence analysis of the fusion protein cleavage site. Because the RRT-PCR primer set used in the assay was designed to amplify the fusion protein shared between all APMV-1 viruses, 19 an END RRT-PCR-negative result having a 100-bp amplicon detected by gel electrophoresis was expected for non-END APMV-1 viruses. APMV-1 Newcastle Disease Virus (NDV), including vaccine strains, and PPMV-1 detection were confirmed using an alternate APMV-1-specific probe and direct sequence analysis of the fusion protein cleavage site. The NDV-specific probe was designed by the Lawrence Livermore National Laboratory r,4 to function with the previously described primer sets but to detect only the cleavage site amino acid pattern specific to lentogenic Newcastle disease virus (data not shown). All discordant results, false negative or false positive, were fully investigated by sequence confirmation, necropsy findings, repeat virus isolation, and epidemiological investigation. Performance criteria and statistical analysis. Analytical sensitivity, defined as the ability to detect all END viruses, was determined using the END viruses encountered during the 2002-2003 outbreak, endpoint dilution of END-positive swab samples, and linearity of the assay using a 10-fold dilution series of reference virus. For analytical specificity, primers and probes were screened in silicio using NCBI Blast (http://www.ncbi.nlm.nih.gov) for potential nonspecific cross-reactions to any published sequences in GenBank, and additionally screened by the Lawrence Livermore National Laboratory in a 96-well format against a panel of 44 selected environmental samples and prokaryotic DNA including insect and avian species samples. 6 Diagnostic sensitivity of the 96-well END RRT-PCR approach was calculated as the proportion of 926 virus isolation END-positive swab samples that were correctly classified by the RRT-PCR alone and by RRT-PCR combined with 4% agarose gel confirmation. Diagnostic specificity was similarly calculated for RRT-PCR alone, and for RRT-PCR with gel confirmation, using virus isolation negative swab samples (n ϭ 434), or using an epidemiologic classification of END negative, which may or may not have included virus isolation (n ϭ 65,345). The epidemiologic classification of END negative included only samples collected after the last confirmed positive END case from the outbreak, so were presumed to be true negative. The samples used in the validation were representative of the species and sample types submitted during the course of the outbreak.
The 95% confidence intervals (CI) for sensitivity (Se) and specificity (Sp) were calculated 8 as:
Descriptive statistics using a commercial spreadsheet, r including mean, standard deviation, r 2 for fit of slope, and PCR Table 1 . Nucleotide sequences END of primers 19 and probe 1, 19 and amino acid sequence of the two END virus types found during the END outbreak in California. The RNA sequence and the translated amino acid sequence detected by the modified Aldous probe 1 
Results
Analytical specificity of the END RRT-PCR, determined by a combination of computer-based and benchlevel screening of primers and probes, 6 demonstrated no false-positive reactions. Evaluation of clinical case material additionally indicated that the assay did not cross-react with Mycoplasma spp., avian influenza virus, avian infectious bronchitis virus, avian laryngotracheitis vaccine strain, or near neighbor APMV-1 or PPMV-1 viruses, including a unique PPMV-1 detected during the outbreak (GenBank accession AY428960). Two END virus fusion protein cleavage site sequences (GenBank accession AY216490 and AY266476) were identified from viruses isolated during the 2002-2003 END outbreak in California, and both were detected by the 96-well RRT-PCR assay ( Table 1 ). The 2 sequences differ in a single nonsynonymous base pair (adenine or guanine) at position 62 of the cited GenBank accession numbers, resulting in either a lysine or arginine at amino acid position 115 of the fusion protein cleavage site. (Table 1 ) Limits of detection and limits of quantitation were evaluated by 10-fold serial dilutions of virus and END virus RNA extracted with the 96-well magnetic bead format. The RRT-PCR was 1-2 logs less sensitive in detecting END virus when compared with virus isolation. The 96-well RRT-PCR assay was linear over 6 logs of virus, with a r 2 value of 0.981 and a slope of Ϫ0.3 ( Table 2 ; Fig. 1 ), indicating 99.53% PCR efficiency. 9 Optimum assay performance for limits of quantitation, with an r 2 Ն 0.99, occurred between Ct 15 and 30. The first 300 positive clinical samples detected using the 96-well END RRT-PCR assay had an average Ct of 19.39 Ϯ 3.97 Ct. Of those 300 positive samples, 97.33% had a Ct of Յ28.0. Diagnostic sensitivity of the 96-well assay, based on correct detection of 923 of 926 samples positive by virus isolation, was 99.67% (95% CI 0.9937, Ͼ 0.9997) ( Table 3 ). Two of the 3 false negatives were swab samples (1 oropharyngeal, 1 cloacal) that originated from game fowl, and the third was a cloacal swab sample taken from a canary. All false negatives obtained using the 96-well END RRT-PCR approach were also negative using the single-tube RRT-PCR assay with the identical primers and probe. The first of 3 false-negative samples using 96-well END RRT-PCR was positive for the appropriate 100bp amplicon by gel electrophoresis and also END positive by virus isolation. Exotic Newcastle Disease virus (GenBank accession AY216490) was subsequently confirmed by sequence analysis of the fusion protein cleavage site using both the alternate primer sets. 5, 19 The second false-negative RRT-PCR sample had no detectable amplicon by agarose gel electrophoresis. Exotic Newcastle Disease virus was recovered by virus isolation and was confirmed by sequence analysis (GenBank accession AY531378), using the 254-bp target, 15 but not the primers for the 202-bp or 100-bp targets. 5, 19 Sequence analysis of the fusion protein Table 2 . cleavage site identified an altered nucleic acid sequence at the forward primer site for the 100-bp primer set, consisting of a base pair change from guanine to adenine (Table 1 ). The final false-negative swab sample was not detected by any combination of RRT-PCR primer sets or assay formats but was positive by virus isolation. There was an insufficient volume of the original swab sample to repeat the virus isolation result.
On the basis of 434 virus isolation negative samples, the diagnostic specificity of the 96-well approach without subsequent agarose gel electrophoresis for confirmation of a 100-bp amplicon was 0.9885 (95% CI 0.9828, Ͼ0.9942), representing 5 false-positive results ( Table 3 , part A). Diagnostic specificity using RRT-PCR with agarose gel confirmation of a 100-bp amplicon yielded no false-positive results ( Table 3 , part B). When 96-well END RRT-PCR assay performance included 65,345 epidemiologically negative samples collected between June and December 2003, after the last confirmed END-positive case, the specificity of RRT-PCR without gel confirmation was 0.9983 (95% CI 0.9980, Ͼ0.9986). One hundred thirteen false-pos-itive results in 65,345 samples were obtained using RRT-PCR without amplicon-size confirmation, and with confirmation, 2 false-positive samples were detected, yielding a specificity of 0.9999 (95% CI 0.9999, Ͼ0.99999).
Assay efficiency (n ϭ 500 plates) included an evaluation of cross-contamination, per sample costs associated with the assay, and technician-time per sample tested. The maximum sample workload per day, based on 3 technicians and 3 thermocyclers, was 184 samples for single-tube RRT-PCR, compared with an average daily workload that peaked at 1,900 samples per day using the 96-well procedure with the same technical and equipment resources. An average technician time of 9.38 minutes per sample extraction was documented for single-tube RRT-PCR, compared with 0.41 minutes per sample for the 96-well format. Assay repeatability, measured as intra-assay variability, was Ͻ0.50 Ct over 32 swab samples tested in triplicate. Assay reproducibility, measured as inter-assay variability of the quality control standards during routine laboratory testing (n ϭ 500 plates) and representing work by 14 different technicians, was 0.7 Ct. The mean difference between the extraction control (extraction plus RRT-PCR steps) and PCR control (RT-PCR steps only) was 0.65 Ct. Assay failure rate, based on previously identified quality control limits was 4.2% (21 in 500 plates), with 2.2% (11 of 500) occurring during initial technician training, and 2% (10 of 500) occurring from documented technical errors, such as an incorrect shaker speed (3 of 10), wrong loading order of the controls (2 of 10), failure of the PCR control (1 of 10), failure of the extraction control (2 of 10), and exceeded limits allowed for the difference between PCR control and the extraction control (3 of 10).
Discussion
A 96-well END RRT-PCR approach was developed to efficiently test avian oropharyngeal and cloacal swab samples for the presence of END virus during the 2002-2003 outbreak. The assay used a previously validated primer and probe set reported to detect the fusion protein cleavage site of representative END virus isolates obtained nationally and internationally. 19 It successfully detected both the END virus fusion cleavage site sequence variations recovered in California during the 2002-2003 outbreak. The high-throughput approach was specifically designed to enhance cost and time efficiency by targeting END detection in a single highly sensitive and specific RRT-PCR assay. The assay was aimed at individual bird samples but was also suitable for flock-based detection to respond to the different avian populations involved in the END outbreak. In comparison, the single-tube assay was designed as a 2-step process; initial screening for all APMV-1 followed by differentiation of END virus in a second RRT-PCR single-tube assay, doubling the technical time and reagents required to report a positive END result. 17, 19 The single-tube APMV-1 screening assay has a sensitivity and specificity of 97.8% and 95.6% respectively, as reported for a combination of swab and tissue samples, and a sensitivity of 96.7% and a specificity of 97.3% for swab samples only. The single-tube END confirmatory RRT-PCR, reported for the combination of swab and tissue samples, has a sensitivity of 78.3% and specificity of 99.1%. The reported sensitivity and specificity for swab samples alone is 92.9% and 99.1%, respectively (Pederson JC, Senne DA, McFarland M, et al: 2003, North Central Avian Disease Conference, Cleveland, OH). The 96well RRT-PCR provided considerably improved diagnostic sensitivity and specificity for swab samples, 99.68% and 99.99%, respectively. Among the 81,943 swab samples evaluated by RRT-PCR during the outbreak, only 5 false-positive and 3 false-negative results were detected. Because of the small number of false test results, no significant differences in sensitivity and specificity could be correlated to different swab types, including oropharyngeal or cloacal swabs, and pooled versus individual swabs using the 96-well approach. However, virus isolation used early in the outbreak demonstrated that tracheal and oropharyngeal swabs had a higher sensitivity than cloacal swabs in detecting END. Sensitivity of virus isolation for tracheal and oropharyngeal swabs was reported as 100% and 99.8%, respectively, compared with 95.6% for cloacal swab samples (F Uzal, 2003, American Association of Veterinary Laboratory Diagnosticians Conference. San Diego, CA). A similar trend was observed with RRT-PCR during development, and oropharyngeal or tra-cheal swab samples were strongly encouraged as the optimum sample, although during the outbreak Ͼ50% of the samples submitted from the task force were cloacal swabs. Tissue samples other than allantoic fluids from virus isolation attempts were not evaluated using the 96-well approach because they did not lend themselves to high-throughput processing, and swab samples could easily be obtained from live birds as well as carcasses. Swab samples collected during the outbreak showed that infected birds shed the virus in relatively high concentrations and anticipated problems associated with a lower detection limit for the RRT-PCR compared with virus isolation were not experienced. Ninety-seven percent of the positive RRT-PCR samples, regardless of being cloacal or oropharyngeal swabs, had Ct values within the linear range of the assay and detected virus at 1 or more logs above the established detection limit of the assay.
Identical primers and probes were used in both assays, so the difference in diagnostic sensitivity between single-tube and 96-well assays was attributed to different RNA extraction methods, as well as modifications in the PCR reagents and cycling conditions. Both single-tube and 96-well assays misclassified 3 virus isolation positive samples as RRT-PCR negative. Three unrelated sources of misclassification were identified; a mutation at the forward primer site of 1 isolate, an unexplained lack of probe binding despite adequate PCR amplification for 1 isolate, and virus present below the limit of detection in a third sample.
The 96-well magnetic bead extraction was selected for adaptability to high-throughput when compared with RNA extractions using chloroform-phenol-based and column-based protocols. The bead extraction approach additionally provides increased purity and higher yields of RNA (X. Fang, personal communication) compared with glass fiber-based extractions. An added advantage of the increased RNA purity was reduced postextraction RNA decay, allowing storage of preloaded RNA/RRT-PCR plates overnight for added time efficiency. Additional assay modifications include lower incubation temperature for the reverse transcriptase, alternate reverse transcriptase enzymes, increased magnesium and dNTP concentrations, and a symmetrical forward primer to reverse primer ratio. The reverse transcriptase used in the 96-well RRT-PCR was selected to reduce overall assay time. The recommended enzyme for the single-tube RRT-PCR requires a 15-minute incubation period for enzyme inactivation before amplification cycles, whereas the enzyme selected for the 96-well assay was inactivated within 2 minutes. The time difference in the 2 protocols was 65 minutes per day (13 minutes ϫ 5 runs), sufficient to add an additional run of 92 samples per thermocycler in an 8-hour work shift.
Although a key advantage of RRT-PCR is the elimination of postamplification detection steps, assay specificity of the 96-well RRT-PCR was further enhanced by routine confirmation of amplicon size during the 2002-2003 outbreak. Using the previously validated 100-bp target primer set, 19 an additional 80-bp PCR product was frequently detected on 4% agarose gels, and presumed to be because of formation of PCR primer-dimers. Assay redesign efforts are currently focused at removing the aberrant primer-dimer reactions. The use of the additional gel electrophoresis confirmation step for RRT-PCR-positive samples enhanced the diagnostic specificity of the 96-well END RRT-PCR by 0.17%, providing a diagnostic specificity equal to virus isolation.
The precision and reproducibility of the assay, monitored by the routine use of both extraction and PCR controls, indicates the 96-well approach is easy to adopt and maintain in a typical laboratory environment having appropriate training and technical skills. Although risk of cross-contamination between wells was identified as a potential drawback of a 96-well PCR format, routine retesting of all END RRT-PCR-positive samples located in adjacent wells indicated no well-to-well carryover or cross-contamination had occurred. The 96-well RRT-PCR protocol described can be completed within 4-6 hours, considerably less time than required for virus isolation and typing.
Initial END control estimates in 2002, which were based on the earlier large outbreak of END in Southern California in the early 1970s, predicted that disease control efforts would ultimately require 2-3 years. The introduction of rapid detection using RRT-PCR and the significant contribution of the high-throughput approach helped reduce the length of the control effort to approximately 11 months. The USDA estimated costs for control of the 2002-2003 END outbreak were more than $160 million, with direct trade impacts through September 2003 estimated at an additional $121 million (http://www.aphis.usda.gov/vs/ceah/cei/ diseasesummary070903.htm). A projected 2-year cost savings of millions of dollars can be directly related to the ability to process significantly more surveillance and disease control samples per day. The 10-fold greater number of samples processed per day using the high-throughput RRT-PCR approach, contributed to more timely release of quarantine zones and associated release of international trade restrictions.
In summary, the high-throughput approach using 96-well extraction and END RRT-PCR is a model for time-and cost-efficient testing, with a reasonable expenditure in technical resources and equipment. The technology used is adaptable to other diagnostic and surveillance PCR-based testing and would be suitable for either exotic or endemic diseases, where there is a requirement to efficiently test large numbers of samples.
